All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EHA2023 abstracts: What’s hot in MPN?
Bookmark this article
To help navigate the exciting content being presented at the EHA2023 Congress, the MPN Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MPN.
Friday, June 9, 2023
Saturday, June 10, 2023
|
Abstract |
Type |
Title |
Presenter |
|
S210 |
Oral presentation |
An open-label, global, phase 1b/2 study adding navtemadlin (NVTM) to ruxolitinib (RUX) in patients with primary or secondary myelofibrosis who have a suboptimal response to RUX |
John Mascarenhas |
|
S211 |
Oral presentation |
Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis: Updated results and genomic characteristics |
Harry Gill |
|
S212 |
Oral presentation |
A randomized double-blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate-2 or high risk myelofibrosis |
Yi Zhang |
|
S213 |
Oral presentation |
BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis: Results from a phase 1/2 study |
Haifa Kathrin |
Sunday, June 11, 2023
|
Abstract |
Type |
Title |
Presenter |
|
LB2710 |
Late breaking oral presentation |
Marina Kremyanskaya |
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox